Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind
published in: Lancet Oncology Commission
date of publication: 2016-03-02
main subject: placebo, multicenter clinical trial, metastatic breast cancer
Cites articles 30
Date
Title
Article - wd:Q39944735